Illumina, Syapse team up for research on biomarker testing patterns in oncology
Illumina (ILMN
-2.6%) is collaborating with Syapse for assessing the real-world uptake and potential use of genomic profiling in the community oncology health system setting.
The companies said the work between them is aimed at understanding biomarker testing patterns and actionability of test results to inform clinical decision-making in the community health system setting for facilitating improved clinical decision making.

The companies added that biomarker testing is used not only to select the most appropriate targeted oncology therapy available on the market for a particular patient but also to determine whether a patientâs best course of action is to receive an experimental therapy as part of a trial.
âThe insights gleaned from this collaboration can help to make that a reality by improving clinical decision making, at both the provider and health system level and ultimately strengthening the delivery of precision oncology care,â said Illumina Chief Medical Officer Phil Febbo.